Net Loss Per Share

6 Months Ended

Jun. 30, 2022

Net Loss Per Share

Net Loss Per Share

11. Net Loss Per Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options, warrants, and unvested restricted stock that are computed using the treasury stock method.

For the quarters ended June 30, 2022 and 2021, all of the Company’s common stock options, unvested restricted stock units and warrants are anti-dilutive and therefore have been excluded from the diluted calculation.

The following table reconciles net loss to net loss attributable to NightHawk Biosciences, Inc.:

	For the Three Months Ended				For the Six Months Ended
	June 30,				June 30,
	2022		2021		2022		2021
Net loss	$	(10,263,910)	$	(6,620,576)	$	(18,453,708)	$	(14,243,716)
Net loss - Non-controlling interest		(106,624)		(77,379)		(175,835)		(168,341)
Net loss attributable to NightHawk	$	(10,157,286)	$	(6,543,197)	$	(18,277,873)	$	(14,075,375)
Weighted-average common shares outstanding, basic and diluted		25,602,965		25,137,466		25,598,481		24,671,281
Net loss per share, basic and diluted	$	(0.40)	$	(0.26)	$	(0.71)	$	(0.57)

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share during the three and six months ended June 30, 2022 and 2021 due to their anti-dilutive effect:

	2022	2021
Outstanding stock options	3,007,986	1,673,804
Restricted stock subject to forfeiture and restricted stock units	46,859	259,874
Outstanding common stock warrants	747,383	747,383